ストックスクリーナーアプリを入手
6.50
1.81%
-0.12
アフターアワーズ：
6.50
前日終値:
$6.62
開ける：
$6.63
24時間の取引高:
1.60M
Relative Volume:
1.19
時価総額：
$658.86M
収益：
-
当期純損益:
$-167.48M
株価収益率:
-3.3333
EPS:
-1.95
ネットキャッシュフロー:
$-197.47M
1週間 パフォーマンス:
-9.60%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
-48.17%
1年 パフォーマンス:
-58.47%
1日の値動き範囲:
$6.475
$6.71
1週間の範囲:
$6.475
$7.13
52週間の値動き範囲:
$6.08
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
名前
Day One Biopharmaceuticals Inc
セクター
電話
650 484-0899
住所
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.50 | 728.80M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-09 | 繰り返されました | Needham | Buy |
| 2024-08-01 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-04-24 | 繰り返されました | Needham | Buy |
| 2023-04-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-02-08 | 開始されました | CapitalOne | Overweight |
| 2023-02-03 | 開始されました | Oppenheimer | Perform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-12-05 | 開始されました | Goldman | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
すべてを表示
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
How Day One Biopharmaceuticals Inc. stock performs during market volatilityFree Access to Community - Newser
Why Day One Biopharmaceuticals Inc. stock attracts strong analyst attentionVerified Chart Patterns - Newser
What makes Day One Biopharmaceuticals Inc. stock price move sharplyCapital Growth Picks - Newser
When the Price of (DAWN) Talks, People Listen - news.stocktradersdaily.com
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wealth Enhancement Advisory Services LLC Makes New $88,000 Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Announces Pricing of Upsized Initial Public Offering - IT Business Net
Day One Biopharmaceuticals, Inc. shares rise 4.16% intraday after positive mid-term outlook from Lonza Group. - AInvest
DAY ONE BIOPHARMACEUTICALS Earnings Preview: Recent $DAWN Insider Trading, Hedge Fund Activity, and More - Nasdaq
AMPY Stock: A Voyage Through Amplify Energy Corp’s Finances - investchronicle.com
(DAWN) On The My Stocks Page - news.stocktradersdaily.com
When Will Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Breakeven? - Yahoo Finance
TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN) - MSN
Day 8 of Loss Streak for Day One Biopharmaceuticals Stock with -11% Return (vs. -49% YTD) [6/18/2025] - Trefis
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Brokerages - Defense World
Pallas Capital Advisors LLC Takes Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Bank of America Corp DE Has $260,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Where are the Opportunities in (DAWN) - news.stocktradersdaily.com
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Day One Appoints Michael Vasconcelles As Head Of Research And Development - MarketScreener
Day One Biopharmaceuticals (DAWN) Welcomes New R&D Leader | DAWN Stock News - GuruFocus
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development - GlobeNewswire
Day One Taps ImmunoGen Executive to Lead R&D: 25-Year Oncology Expert Joins Cancer Drug Developer - Stock Titan
H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PT - MSN
Ameriprise Financial Inc. Decreases Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Squarepoint Ops LLC Acquires New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - Insider Monkey
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301 - Seeking Alpha
Nuveen Asset Management LLC Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Millennium Management LLC - Defense World
ProShare Advisors LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,894 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Cetera Investment Advisers Has $400,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
36,685 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by BNP Paribas Financial Markets - Defense World
D. E. Shaw & Co. Inc. Increases Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth - Yahoo Finance
Northern Trust Corp Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day one Biopharmaceuticals officer sells $24,574 in stock By Investing.com - Investing.com Nigeria
Day one Biopharmaceuticals officer sells $24,574 in stock - Investing.com
Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView
Day one biopharmaceuticals highlights OJEMDA revenue growth and pipeline progress in Q1 2025 - MSN
Day One Biopharmaceuticals Insider Lowered Holding By 20% During Last Year - simplywall.st
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stake Decreased by Voya Investment Management LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? - MSN
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Day One Biopharmaceuticals Inc (DAWN) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):